Evidence map›Paper›PMID 16816356›Full record

ReviewThe American journal of pathology2006

Role of the Survivin gene in pathophysiology.

Fengzhi Li, Michael G Brattain

Open access · bronzeAbstract readReview
In one paragraph

Review in The American journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 109 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Correlation between survivin genetic polymorphisms and lung cancer susceptibility.International journal of clinical and experimental pathology · 2015
    Article
  12. Article
  13. Article
  14. Targeting survivin in cancer.Cancer letters · 2013
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Fengzhi LiDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. fengzhi.li@roswellpark.org
Michael G Brattain
Grace (United States) · USRoswell Park Comprehensive Cancer Center · US

Funding

HETEROGENEITY OF HUMAN COLONIC CARCINOMAR01CA034432 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI BRATTAIN, MICHAEL G · 1985 to 2013
$3.8M
Cell Survival Determinants of Metastasis in IGF1R-Dependent CRCR01CA054807 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI BLACK, JENNIFER D. · 1991 to 2016
$3.7M
MECHANISM OF ACTION OF DIFFERENTIATION AGENTSR37CA038173 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRATTAIN, MICHAEL G · 2001 to 2008
$3.1M
AUTOCRINE TGF BETA AND CELL DEATHR01CA072001 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI BRATTAIN, MICHAEL G · 1997 to 2011
$2.8M
MECHANISM OF ACTION OF DIFFERENTIATION AGENTSR01CA038173 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI BRATTAIN, MICHAEL G · 1986 to 2014
$1.8M
Survivin expression and cancer cell drug resistanceR01CA109481 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LI, FENGZHI · 2004 to 2008
$1.2M
NCI NIH HHS R01 CA034432NCI NIH HHS R01 CA038173NCI NIH HHS R01 CA054807NCI NIH HHS R01 CA072001NCI NIH HHS R01 CA109481NCI NIH HHS R37 CA038173
6 · The paper itself

Abstract

Although the roles of survivin in control of cancer cell division and apoptosis as well as targeting survivin for cancer therapeutics have been extensively explored and reviewed, the pathophysiological role of survivin in normal human cells/organs has not been deeply investigated or sufficiently reviewed. Studies in the latter area, however, appear to be important for the identification of different mechanisms of regulation and function of survivin in normal versus abnormal cells and tissues (including cancer), which might ultimately provide the basis for novel approaches for disease treatment with low toxicity. This Review is intended to summarize current observations in the literature related to the physiological and/or pathological roles for survivin in various normal human cells or organs. Our view of potential future research directions for survivin pertinent to potential therapeutic applications will also be discussed.

Indexed as

AnimalsHumansInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsNeoplasm ProteinsSurvivinBIRC5 protein, humanInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsNeoplasm ProteinsSurvivin

Identifiers

PMID16816356
PMCPMC1698749
OpenAlexW684291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.